Kevin Mohammed

Kevin Mohammed

Auto-generated profile, based on publicly available information

Kevin Mohammed

Icahn School of Medicine at Mount Sinai 1 New York, NY

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2025 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SMSlim Mzoughi
Slim Mzoughi
MSMegan Schwarz
Megan Schwarz
XWXuedi Wang
Xuedi Wang
DDDeniz Demircioglu
Deniz Demircioglu
GUGulay Ulukaya
Gulay Ulukaya
Ernesto GuccioneErnesto Guccione
Ernesto Guccione
Targeting cancer stem cells (CSCs) is crucial for effective cancer treatment, yet resistance mechanisms to LGR5+ CSC depletion in WNT-driven colorectal cancer (CRC) remain elusive. In the present study, we revealed that mutant intestinal stem cells (SCs) depart from their canonical identity, traversing a dynamic phenotypic spectrum. This enhanced plasticity is initiated by oncofetal (OnF) reprogramming, driven by YAP and AP-1, with subsequent AP-1 hyperactivation promoting lineage infidelity. The retinoid X receptor serves as a gatekeeper of OnF reprogramming and its deregulation after adenomatous polyposis coli (APC) loss of function establishes an OnF ‘memory’ sustained by YAP and AP-1. Notably, the clinical significance of OnF and LGR5+ states in isolation is constrained by their functional redundancy. Although the canonical LGR5+ state is sensitive to the FOLFIRI regimen, an active OnF program correlates with resistance, supporting its role in driving drug-tolerant states. Targeting this program in combination with the current standard of care is pivotal for achieving effective and durable CRC treatment.

7 June 2024 in Science Advances
Verified
Journal Article
Open access
PHPhuong Mai Hoang
Phuong Mai Hoang
DTDenis Torre
Denis Torre
PJPatrick Jaynes
Patrick Jaynes
JHJessica Ho
Jessica Ho
KMKevin Mohammed
Kevin Mohammed
AJAnand D. Jeyasekharan
Anand D. Jeyasekharan
DNA replication stress (RS) is a widespread phenomenon in carcinogenesis, causing genomic instability and extensive chromatin alterations. DNA damage leads to activation of innate immune signaling, but little is known about transcriptional regulators mediating such signaling upon RS. Using a chemical screen, we identified protein arginine methyltransferase 5 (PRMT5) as a key mediator of RS-dependent induction of interferon-stimulated genes (ISGs). This response is also associated with reactivation of endogenous retroviruses (ERVs). Using quantitative mass spectrometry, we identify proteins with PRMT5-dependent symmetric dimethylarginine (SDMA) modification induced upon RS. Among these, we show that PRMT5 targets and modulates the activity of ZNF326, a zinc finger protein essential for ISG response. Our data demonstrate a role for PRMT5-mediated SDMA in the context of RS-induced transcriptional induction, affecting physiological homeostasis and cancer therapy.

29 September 2026 in Cancer Discovery
Verified
Journal Article
Closed access
AOAna Orive-Ramos
Ana Orive-Ramos
BGBijaya Gaire
Bijaya Gaire
Christos AdamopoulosChristos Adamopoulos
Christos Adamopoulos
BBBeau Baars
Beau Baars
MDMathieu Desaunay
Mathieu Desaunay
PPPoulikos I. Poulikakos
Poulikos I. Poulikakos
Effective MAPK-targeted therapies require greater pathway inhibition in tumors than in normal tissues. Although pan-RAF inhibitors have demonstrated activity in RAS-mutant cancers, combinations with MEK inhibitors require dose reductions because of toxicity, limiting clinical benefit. Here, we show that this toxicity results from MEK inhibitor-mediated feedback relief, which promotes RAF activation and enhances pan-RAF inhibitor binding in normal cells. We identify a distinct mechanism of RAF inhibition by RAF/MEK glues: by stabilizing RAF-MEK complexes, these compounds trap RAF in the cytosol, preventing membrane recruitment required for RAF activation. This spatial modulation mechanism preserves tumor-selective MAPK inhibition and enables full-dose combination therapy with pan-RAF inhibitors. This therapeutic strategy produced robust tumor regressions in multiple RAS-mutant tumor models, including models refractory to current RAS/MAPK-targeting therapies. Our findings underscore drug-induced proximity as a strategy to achieve tumor selectivity and support the clinical development of RAF/MEK glue plus pan-RAF inhibitor combinations for RAS-mutant tumors.